Clinical Trial Update: A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the safety, tolerability, and activity of oral SRT2104 in Type 2 diabetes mellitus. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SRT2104 (SRT2104)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED